Clerk of the House of Representatives	Secretary of the Senate
Legislative Resource Center	Office of Public Records
B-106 Cannon Building	232 Hart Building
Washington, DC 20515	Washington, DC 20510

SECRETARY OF THE SENATE

04 JUL -1 PM 2:37

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

1. Registrant Name
Jorden Burt LLP

2. Address ☐ Check if different than previously reported
1025 Thomas Jefferson St, NW, Suite 400 East

3. Principal Place of Business (if different from line 2)

City: **Washington** State/Zip (or Country) **DC 20007**

4. Contact Name	Telephone	E-mail (optional)	5. Senate ID #
Marilyn Berry Thompson	**202-965-8122**	**mbt@wdc.jordenusa.com**	**43398-595**

7. Client Name Self X	6. House ID #
Kos Pharmaceuticals, Inc.	**31413035**

TYPE OF REPORT

8. Year 2002 Midyear (January 1-June 30) ☐ **OR** Year End (July 1-December 31) X

9. Check if this filing amends a previously filed version of this report ☐

10. Check if this is a Termination Report ☐ ⇨ Termination Date _____ 11. No Lobbying Activity X

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

12. Lobbying Firms

INCOME relating to lobbying activities for this reporting period was:

Less than $10,000 ☐

$10,000 or more X ⇨ $ 20,000
Income (nearest ($20,000)

Provide a good faith estimate, rounded to the nearest $20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

13. Organizations

EXPENSES relating to lobbying activities for this reporting period were:

Less than $10,000 ☐

$10,000 or more ☐ ⇨ $_____
Income (nearest ($20,000)

14. REPORTING METHOD. Check box to indicate expense accounting method. See instructions for description of options.

☐ **Method A.** Reporting amounts using LDA definitions only
☐ **Method B.** Reporting amounts under section 6033(b)(8) of the Internal Revenue Code

☐ **Method C.** Reporting amounts under section 162(e) of the Internal Revenue Code

Signature Marilyn Berry Thompson Date 5/11/04

Printed Name and Title **Marilyn Berry Thompson, Director , Jorden Burt Government Relations**

Form LD-2 (Rev. 6/98)

Registrant Name **Jorden Burt, LLP** Client Name **Kos Pharmaceuticalks, Inc.**

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** provide information as requested. Attach additional page(s) as needed.

15. General issue area code **PHA** (One per page)

16. Specific lobbying issues

S. 54 - Greater Access to Affordable Pharmaceuticals Act
S 1/ HR 1 – Prescription Drug and Medicare Modernization Act
HR 2427 – Pharmaceutical Market Access Act of 2003
Various Drug Reimportation and Generic Drug Proposals

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

United States House of Representatives
United States Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Marilyn Berry Thompson	
Ryan Haaker	

19. Interest of each foreign entity in the specific issues listed on line 16 above **X** Check if None

Signature Marilyn Berry Thompson Date 5/11/04

Printed Name and Title Marilyn Berry Thompson, Director, Jorden Burt Government Relations

Registrant Name Jorden Burt, LLP Client Name **Kos Pharmaceuticals, Inc.**

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** provide information as requested. Attach additional page(s) as needed.

15. General issue area code **HCR** (One per page)

16. Specific lobbying issues

S. 54 - Greater Access to Affordable Pharmaceuticals Act
S 1/ HR 1 – Prescription Drug and Medicare Modernization Act
HR 2427 – Pharmaceutical Market Access Act of 2003
Various Drug Reimportation and Generic Drug Proposals

17. House(s) of Congress and Federal agencies contacted ❑ Check if None

United States House of Representatives
United States Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Marilyn Berry Thompson	
Ryan Haaker	

19. Interest of each foreign entity in the specific issues listed on line 16 above **X** Check if None

Signature Marilyn Berry Thompson Date 5/11/04

Printed Name and Title Marilyn Berry Thompson, Director, Jorden Burt Government Relations

Form LD-2 (Rev. 6/98)

Registrant Name **Jorden Burt, LLP** Client Name **Kos Pharmaceuticals, Inc.**

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** provide information as requested. Attach additional page(s) as needed.

15. General issue area code **MMM** (One per page)

16. Specific lobbying issues

S. 54 - Greater Access to Affordable Pharmaceuticals Act
S 1/ HR 1 – Prescription Drug and Medicare Modernization Act
HR 2427 – Pharmaceutical Market Access Act of 2003
Various Drug Reimportation and Generic Drug Proposals

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

United States House of Representatives
United States Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Marilyn Berry Thompson	
Ryan Haaker	

19. Interest of each foreign entity in the specific issues listed on line 16 above **X** Check if None

Signature Marilyn Berry Thompson Date 5/11/04

Printed Name and Title Marilyn Berry Thompson, Director, Jorden Burt Government Relations

Registrant Name **Jorden Burt, LLP** Client Name **Kos Pharmaceuticals, Inc.**

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** provide information as requested. Attach additional page(s) as needed.

15. General issue area code **MED** (One per page)

16. Specific lobbying issues

S. 54 - Greater Access to Affordable Pharmaceuticals Act
S 1/ HR 1 – Prescription Drug and Medicare Modernization Act
HR 2427 – Pharmaceutical Market Access Act of 2003
Various Drug Reimportation and Generic Drug Proposals

17. House(s) of Congress and Federal agencies contacted ❑ Check if None

United States House of Representatives
United States Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Marilyn Berry Thompson	
Ryan Haaker	

19. Interest of each foreign entity in the specific issues listed on line 16 above **X** Check if None

Signature Marilyn Berry Thompson Date 5/11/04

Printed Name and Title Marilyn Berry Thompson, Director, Jorden Burt Government Relations

Registrant Name **Jorden Burt, LLP** Client Name **Kos Pharmaceuticals, Inc.**

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** provide information as requested. Attach additional page(s) as needed.

15. General issue area code **CPT** (One per page)

16. Specific lobbying issues

Patent Extension and Market Exclusivity Regulations

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

United States House of Representatives
United States Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Marilyn Berry Thompson	
Ryan Haaker	

19. Interest of each foreign entity in the specific issues listed on line 16 above **X** Check if None

Signature Marilyn Berry Thompson Date 5/11/04

Printed Name and Title Marilyn Berry Thompson, Director, Jorden Burt Government Relations

Form LD-2 (Rev. 6/98)

ACC	Accounting
ADV	Advertising
AER	Aerospace
AGR	Agriculture
ALC	Alcohol & Drug Abuse
ANI	Animals
APP	Apparel/Clothing Industry/Textiles
ART	Arts/Entertainment
AUT	Automotive Industry
AVI	Aviation/Aircraft/Airlines
BAN	Banking
BNK	Bankruptcy
BEY	Beverage Industry
BUD	Budget/Appropriations
CHM	Chemicals/Chemical Industry
CIV	Civil Rights/Civil Liberties
CAW	Clean Air & Water (Quality)
CDT	Commodities (Big Ticket)
COM	Communications/Broadcasting/Radio/TV
CPI	Computer Industry
CSP	Consumer Issues/Safety/Protection
CON	Constitution
CPT	Copyright/Patent trademark
DEF	Defense
DOC	District of Columbia
DIS	Disaster Planning/Emergencies
ECN	Economics/Economic Development
EDU	Education
ENG	Energy/Nuclear
ENV	Environmental/Superfund
FAM	Family Issues/Abortion/Adoption
FIR	Firearms/Guns/Ammunition
FIN	Financial Institutions/Investments/Securities
FOO	Food Industry (Safety, Labeling, etc.)
FOR	Foreign Relations
FILE	Fuel/Gas/Oil
GAM	Gaming/Gambling/Casino
GOV	Government Issues
HCR	Health Issues
HOU	Housing
IMM	Immigration
IND	Indian/Native American Affairs
INS	Insurance
LBR	Labor Issues/Antitrust/Workplace ace
LAW	Law Enforcement/Crime/Criminal Jus
MAN	Manufacturing
MAR	Marine/Maritime/Boating/Fisheries
MIA	Media (Information/Publishing)
MED	Medical/Disease Research/Clinical La
MMM	Medicare/Medicaid
MON	Minting/Money/Gold Standard
NAT	Natural Resources
PHA	Pharmacy
POS	Postal
RRR	Railroads
RES	Real Estate/Land Use/Conservation
REL	Religion
RET	Retirement
ROD	Roads/Highway
SCI	Science/Technology
SMB	Small Business
SPO	Sports/Athletics
TAX	Taxation/Internal Revenue Code
TEC	Telecommunications
TOB	Tobacco
TOR	Torts
TRD	Trade (Domestic & Foreign)
TRA	Transportation
TOU	Travel/Tourism
TRU	Trucking/Shipping
URB	Urban Development/Municipalities
UNM	Unemployment
UTI	Utilities
VET	Veterans
WAS	Waste (hazardous/solid/interstate/nuc
WEL	Welfare